Literature DB >> 33515112

RHBDD1 silencing inhibited cell growth and invasion of non-small cell lung cancer by mediating ZEB1/PI3K/AKT signaling pathway.

Zheyuan Xu1, Ran Wang2, Xu Li1, Limin Yang1, Hao Peng3, Yang Wang1, Ping Wang4.   

Abstract

Rhomboid domain containing 1 (RHBDD1) gene, which was reported to be upregulated in human several cancer, was associated with carcinogenesis. However, the potential biological function of RHBDD1 in non-small cell lung cancer (NSCLC) carcinogenesis remains still not known. In this study, we aimed to investigate the role of RHBDD1 and its underlying molecular mechanism in NSCLC. The gene RHBDD1 expression was detected in NSCLC tissues and matched nontumor adjacent tissues. In vitro experiments, NSCLC cell lines (A549, H1650, H358 and H1299) were performed to investigate the biological function of RHBDD1 and its molecular mechanism. Our findings showed that the mRNA and protein expression levels of RHBDD1 were notably increased in human NSCLC tissues and cell lines, especially in A549 and H1650 cells. Moreover, silencing of RHBDD1 by RNAi notably inhibited NSCLC cell proliferation and increased cell apoptosis. Caspase-3/7 activity was remarkably increased in cells treated with RHBDD1 siRNA. RHBDD1 silencing notably reduced the number of invading cells. Furthermore, our findings showed that silencing of RHBDD1 notably inhibited the mRNA and protein expression levels of ZEB1 in A549 and H1650 cells. The phosphorylation of PI3K and AKT was also remarkably decreased by RHBDD1 silencing. ZEB1/AKT overexpression reversed the effect of RHBDD1 silencing on NSCLC cell growth and invasion. Taken together, our findings indicated that RHBDD1 silencing inhibited cell growth and invasion of non-small cell lung cancer by mediating ZEB1/PI3K/AKT signaling pathway, implying that RHBDD1 was possibly a potential diagnostic and therapeutic target for NSCLC treatment.

Entities:  

Keywords:  Cell growth; Invasion; Non-small cell lung cancer; RHBDD1; ZEB1

Year:  2021        PMID: 33515112     DOI: 10.1007/s10735-020-09943-z

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  22 in total

Review 1.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

2.  Jagged1 is Clinically Prognostic and Promotes Invasion of Glioma-Initiating Cells by Activating NF-κB(p65) Signaling.

Authors:  Long Hai; Peidong Liu; Shengping Yu; Li Yi; Zhennan Tao; Chen Zhang; Iruni Roshanie Abeysekera; Tao Li; Luqing Tong; Haiwen Ma; Bo Liu; Yang Xie; Xingchen Zhou; Yu Lin; Meng Zhu; Kai Zhang; Bingcheng Ren; Haolang Ming; Yubao Huang; Xuejun Yang
Journal:  Cell Physiol Biochem       Date:  2018-10-11

Review 3.  Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.

Authors:  Claudia Fumarola; Mara A Bonelli; Pier Giorgio Petronini; Roberta R Alfieri
Journal:  Biochem Pharmacol       Date:  2014-05-24       Impact factor: 5.858

Review 4.  Pleiotropic Roles for ZEB1 in Cancer.

Authors:  Julie Caramel; Maud Ligier; Alain Puisieux
Journal:  Cancer Res       Date:  2017-12-18       Impact factor: 12.701

Review 5.  Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.

Authors:  Narjust Duma; Rafael Santana-Davila; Julian R Molina
Journal:  Mayo Clin Proc       Date:  2019-08       Impact factor: 7.616

Review 6.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

Review 7.  Gene expression profiling for early-stage NSCLC.

Authors:  Frunze Petrosyan; Hamed Daw; Abdo Haddad; Timothy Spiro; Ruchi Sood
Journal:  Am J Clin Oncol       Date:  2015-02       Impact factor: 2.339

Review 8.  Understanding and targeting resistance mechanisms in NSCLC.

Authors:  Julia Rotow; Trever G Bivona
Journal:  Nat Rev Cancer       Date:  2017-10-25       Impact factor: 60.716

Review 9.  The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review.

Authors:  M Monticelli; P Zeppa; F Zenga; R Altieri; M Mammi; L Bertero; I Castellano; P Cassoni; A Melcarne; G La Rocca; G Sabatino; A Ducati; D Garbossa
Journal:  Clin Neurol Neurosurg       Date:  2018-07       Impact factor: 1.876

10.  Silencing of rhomboid domain containing 1 to inhibit the metastasis of human breast cancer cells in vitro.

Authors:  Chunjun Huang; Xiaochun Ji; Yinyin Peng; Minghua Wu; Weizhu Wu; Yong Luo; Gaoxiang Cheng; Ye Zhu
Journal:  Iran J Basic Med Sci       Date:  2018-11       Impact factor: 2.699

View more
  1 in total

1.  The mammalian rhomboid protein RHBDL4 protects against endoplasmic reticulum stress by regulating the morphology and distribution of ER sheets.

Authors:  Viorica L Lastun; Clémence Levet; Matthew Freeman
Journal:  J Biol Chem       Date:  2022-04-15       Impact factor: 5.486

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.